Clinical Trials Related to HR+/HER2- Breast Cancer

Related studies linked through entity extraction aliases.

Pre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast Cancer

Status: RECRUITING
Phase: N/A

Kumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast Cancer

Status: NOT_YET_RECRUITING
Phase: PHASE2

BGB-43395 Plus Letrozole Versus CDK4/6i Plus Letrozole for Patients With Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Treatment for Advanced or Metastatic Disease

Status: RECRUITING
Phase: PHASE3

Marker - Adjusted Therapy Comparing Adjuvant Elacestrant With Standard Endocrine Treatment in Genomically and/or Clinically High-risk ER+/HER2- eBC

Status: RECRUITING
Phase: PHASE3

Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests

Status: RECRUITING
Phase: PHASE3

ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors

Status: RECRUITING
Phase: PHASE1/PHASE2

Serplulimab Combined With Chemotherapy for Early-stage HR+/HER2- Breast Cancer

Status: RECRUITING
Phase: PHASE2